Clinical Pharmacology and Therapeutics
-
Publication Venue For
- Population Pharmacokinetics of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: An Integrated Analysis.. 112:1061-1069. 2022
- Use of Real-World Data and Physiologically-Based Pharmacokinetic Modeling to Characterize Enoxaparin Disposition in Children With Obesity.. 112:391-403. 2022
- Development of a Generic Physiologically-Based Pharmacokinetic Model for Lactation and Prediction of Maternal and Infant Exposure to Ondansetron via Breast Milk.. 111:1111-1120. 2022
- SLCO1B1*5 Allele Is Associated With Atorvastatin Discontinuation and Adverse Muscle Symptoms in the Context of Routine Care.. 111:1075-1083. 2022
- The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms.. 111:1007-1021. 2022
- When Are Treatment Blinding and Treatment Standardization Necessary in Real-World Clinical Trials?. 111:116-121. 2022
- When Can We Rely on Real-World Evidence to Evaluate New Medical Treatments?. 111:30-34. 2022
- Lessons Learned Using Real-World Data to Emulate Randomized Trials: A Case Study of Treatment Effectiveness for Newly Diagnosed Immune Thrombocytopenia.. 110:1570-1578. 2021
- Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy.. 110:888-896. 2021
- Seeking Similarities Rather Than Differences With Adults to Aid in Therapeutic Advancement for Children.. 110:11-14. 2021
- Physiologically-Based Pharmacokinetic Modeling Characterizes the CYP3A-Mediated Drug-Drug Interaction Between Fluconazole and Sildenafil in Infants.. 109:253-262. 2021
- Relationship Between Progression-Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD-1/PD-L1 Immune Checkpoint Blockade: A Meta-Analysis.. 108:1274-1288. 2020
- Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium.. 108:1067-1077. 2020
- Stereoselective Steady-State Disposition and Bioequivalence of Brand and Generic Bupropion in Adults.. 108:1036-1048. 2020
- Genomewide Meta-Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy.. 108:625-634. 2020
- Population Analysis of Anidulafungin in Infants to Older Adults With Confirmed or Suspected Invasive Candidiasis.. 108:316-325. 2020
- Managing Increased Accessibility to Pharmacogenomic Data.. 106:922-924. 2019
- Pharmacogenomics-Driven Prediction of Antidepressant Treatment Outcomes: A Machine-Learning Approach With Multi-trial Replication.. 106:855-865. 2019
- Genetic Variants Associated With Vincristine-Induced Peripheral Neuropathy in Two Populations of Children With Acute Lymphoblastic Leukemia.. 105:1421-1428. 2019
- Bioequivalence and Therapeutic Equivalence of Generic and Brand Bupropion in Adults With Major Depression: A Randomized Clinical Trial.. 105:1164-1174. 2019
- A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance).. 105:738-745. 2019
- A Novel Method to Estimate Long-Term Chronological Changes From Fragmented Observations in Disease Progression.. 105:436-447. 2019
- On Bayesian Analysis and Hypothesis Testing in the Determination of Bioequivalence.. 105:304-306. 2019
- Common Polymorphisms of CYP2B6 Influence Stereoselective Bupropion Disposition.. 105:142-152. 2019
- Pharmacologic Targeting of Red Blood Cells to Improve Tissue Oxygenation.. 104:553-563. 2018
- Leveraging Big Data in Pediatric Development Programs: Proceedings From the 2016 American College of Clinical Pharmacology Annual Meeting Symposium.. 104:81-87. 2018
- Wearable Devices in Clinical Trials: Hype and Hypothesis.. 104:42-52. 2018
- Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects.. 103:778-786. 2018
- Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status.. 103:631-642. 2018
- Comparison of Outcomes Following a Switch From a Brand to an Authorized Versus Independent Generic Drug.. 103:310-317. 2018
- Emerging Therapies for Congestive Heart Failure.. 103:77-87. 2018
- Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.. 102:37-44. 2017
- Cancer Moonshot Data and Technology Team: Enabling a National Learning Healthcare System for Cancer to Unleash the Power of Data.. 101:613-615. 2017
- Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update.. 99:36-37. 2016
- Metabolomic Signatures for Drug Response Phenotypes: Pharmacometabolomics Enables Precision Medicine.. 98:71-75. 2015
- Pharmacokinetics, Pharmacodynamics, and Safety of Lisinopril in Pediatric Kidney Transplant Patients: Implications for Starting Dose Selection.. 98:25-33. 2015
- Results from the IQ-CSRC prospective study support replacement of the thorough QT study by QT assessment in the early clinical phase.. 97:326-335. 2015
- Phenotype standardization for statin-induced myotoxicity.. 96:470-476. 2014
- The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.. 96:423-428. 2014
- Use of opportunistic clinical data and a population pharmacokinetic model to support dosing of clindamycin for premature infants to adolescents.. 96:429-437. 2014
- Improving the assessment of heart toxicity for all new drugs through translational regulatory science.. 95:501-508. 2014
- Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.. 95:376-382. 2014
- Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens.. 95:141-146. 2014
- Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology.. 95:154-167. 2014
- Integration of pharmacometabolomic and pharmacogenomic approaches reveals novel insights into antiplatelet therapy.. 94:570-573. 2013
- Pharmacometabolomics of statin response.. 94:562-565. 2013
- Purine pathway implicated in mechanism of resistance to aspirin therapy: pharmacometabolomics-informed pharmacogenomics.. 94:525-532. 2013
- Therapeutic implications of biomarkers in chronic heart failure.. 94:468-479. 2013
- A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics.. 94:394-399. 2013
- Biomarkers for smoking cessation.. 93:526-538. 2013
- Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants.. 93:402-408. 2013
- A network-heuristic approach to improve the impact of genomic data on drug discovery.. 93:295-297. 2013
- Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.. 93:153-158. 2013
- Drug shortages in the United States: a critical evaluation of root causes and the need for action.. 93:133-135. 2013
- Using genetics to enable studies on the prevention of Alzheimer's disease.. 93:177-185. 2013
- The effects of heparins on the liver: application of mechanistic serum biomarkers in a randomized study in healthy volunteers.. 92:214-220. 2012
- The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.. 92:112-117. 2012
- Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics.. 91:673-684. 2012
- Optimization of pediatric rheumatology therapeutics.. 91:597-606. 2012
- Impediments to clinical research in the United States.. 91:535-541. 2012
- Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype.. 91:321-326. 2012
- Rational opioid dosing in the elderly: dose and dosing interval when initiating opioid therapy.. 91:339-343. 2012
- Pharmacodynamic evaluation of clopidogrel plus PA32540: the Spaced PA32540 With Clopidogrel Interaction Gauging (SPACING) study.. 90:860-866. 2011
- Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response.. 90:568-574. 2011
- The Achilles' heel of cardiovascular genetic testing: distinguishing pathogenic mutations from background genetic noise.. 90:496-499. 2011
- Practical ethics: establishing a pathway to benefit for complex pharmacogenomic tests.. 90:25-27. 2011
- Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimal and noninvasive probes for hepatic and first-pass CYP3A induction.. 90:100-108. 2011
- Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates.. 89:702-707. 2011
- Concurrent assessment of hepatic and intestinal cytochrome P450 3A activities using deuterated alfentanil.. 89:562-570. 2011
- Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics.. 89:97-104. 2011
- Genetic variation in IL28B: impact on drug development for chronic hepatitis C infection.. 88:708-711. 2010
- Cough in pediatric patients receiving angiotensin-converting enzyme inhibitor therapy or angiotensin receptor blocker therapy in randomized controlled trials.. 87:668-671. 2010
- How informatics can potentiate precompetitive open-source collaboration to jump-start drug discovery and development.. 87:614-616. 2010
- The Biomarkers Consortium: practice and pitfalls of open-source precompetitive collaboration.. 87:539-542. 2010
- A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans.. 87:445-451. 2010
- Safety and pharmacokinetics of repeat-dose micafungin in young infants.. 87:93-99. 2010
- Clinical trial design in neonatal pharmacology: effect of center differences, with lessons from the Pediatric Oncology Cooperative Research experience.. 86:589-591. 2009
- From trial and error to trial simulation. Part 2: an appraisal of current beliefs in the design and analysis of clinical trials for antidepressant drugs.. 86:255-262. 2009
- QT as a safety biomarker in drug development.. 86:101-104. 2009
- Abacavir pharmacokinetics during chronic therapy in HIV-1-infected adolescents and young adults.. 85:394-401. 2009
- Racial differences in blood pressure response to angiotensin-converting enzyme inhibitors in children: a meta-analysis.. 84:315-319. 2008
- Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.. 84:326-331. 2008
- Adverse drug reactions with halogenated anesthetics.. 84:158-162. 2008
- Anesthesia: a discipline that incorporates clinical pharmacology across the DDRU continuum.. 84:3-6. 2008
- Inhaled anesthesia: the original closed-loop drug administration paradigm.. 84:15-18. 2008
- Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes.. 84:83-89. 2008
- Processed EEG (bispectral index) is not appropriate for characterizing opioid sedation.. 83:667-668. 2008
- Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo.. 83:77-85. 2008
- Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response.. 83:160-166. 2008